Yes, I would love big news to drop giving a very successful TO. It would be nice to have enough cash to not be in fundraising mode for once. That also gives more leverage in a partnership deal. Though at this mc, they probably will need to get the BLA submitted or other big news items, and let the mc appreciate before BP is willing to put down big money for hiv. Eliminating the downward pressure on the mc from dilutive fundraising would be a great step towards helping the mc appreciate. I’ve been in other stock in similar financial situations and once the sp takes off, they went from zero to hero, from few takers or bad offers to everyone wanting a piece of the action. But the Chinese deal or Samsung deal for say 20M would kick start the movement also. Last big movement was the Charlie Sheen effect years ago, I knew about with the sp, but didn’t realize it was so big for HIV in general until reading this on wiki a couple weeks ago.
The Charlie Sheen Effect
Sheen's HIV-positive disclosure corresponded with the greatest number of HIV-related Google searches ever recorded in the United States. During the 3 weeks following his disclosure, there were about 2.75 million more searches than expected that included the term HIV, and 1.25 million searches were directly relevant to public-health outcomes because they included search terms for condoms, HIV symptoms, or HIV testing (e.g., "get HIV tested"
.[114]
A later study found Sheen's disclosure corresponded with a 95% increase in over-the-counter at-home HIV testing kits.[115]
The study's authors dubbed it "The Charlie Sheen Effect" with commenters noting "Charlie Sheen did more for HIV education than most UN events do."[116] Sheen spoke out for HIV prevention, citing the studies as motivation, later adding he was "humbled" to "be of service."
Another Side note—More MS research linking cleared virus with continued ccl5 production promoting the lesion sites.
OTTAWA, Ontario, July 2, 2019 /PRNewswire/ -- Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine [1].
Viral infection early in life is a key element in determining the risk of subsequent development of multiple sclerosis (MS). Scientists from the Faculty of Medicine of the University of Geneva (UNIGE) and the University Hospitals of Geneva led by Professor Doron Merkler have published a high-profile paper describing a new preclinical MS model that incorporates early life viral infection in the brain. In this model, sites of cleared virus become lesion sites associated with MS-like pathology when experimental autoimmune encephalomyelitis (EAE) is subsequently induced. EAE lesions contain high levels of inflammatory leukocytes that infiltrate because the sites of cleared virus are long-term sites of production of CCL5, a natural ligand of the chemokine receptor CCR5. Systemic administration of Orion Biotechnology's best-in-class CCR5 blocker OB-002 was sufficient to fully block both the development of these leukocyte-infiltrated lesions and the associated pathology.
"It is very exciting to have identified a possible pathway linking virus infection early in life to MS pathology, and intriguing that it should be dependent on the activation of a single chemokine receptor," said Prof. Merkler.
"We are thrilled to see that OB-002 shows such high efficacy in this preclinical context," said Professor Oliver Hartley, a co-author of the paper from the University of Geneva, and Vice-President for Drug Discovery at Orion Biotechnology. "These data provide a clear rationale to move forward with the development of OB-002 as novel agent for the treatment of MS."
Mark Groper, President & CEO of Orion Biotechnology, commented, "We are pleased to be working with the University of Geneva and look forward to further collaboration based on these encouraging preclinical findings."
The Charlie Sheen Effect
Sheen's HIV-positive disclosure corresponded with the greatest number of HIV-related Google searches ever recorded in the United States. During the 3 weeks following his disclosure, there were about 2.75 million more searches than expected that included the term HIV, and 1.25 million searches were directly relevant to public-health outcomes because they included search terms for condoms, HIV symptoms, or HIV testing (e.g., "get HIV tested"
.[114] A later study found Sheen's disclosure corresponded with a 95% increase in over-the-counter at-home HIV testing kits.[115]
The study's authors dubbed it "The Charlie Sheen Effect" with commenters noting "Charlie Sheen did more for HIV education than most UN events do."[116] Sheen spoke out for HIV prevention, citing the studies as motivation, later adding he was "humbled" to "be of service."
Another Side note—More MS research linking cleared virus with continued ccl5 production promoting the lesion sites.
OTTAWA, Ontario, July 2, 2019 /PRNewswire/ -- Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine [1].
Viral infection early in life is a key element in determining the risk of subsequent development of multiple sclerosis (MS). Scientists from the Faculty of Medicine of the University of Geneva (UNIGE) and the University Hospitals of Geneva led by Professor Doron Merkler have published a high-profile paper describing a new preclinical MS model that incorporates early life viral infection in the brain. In this model, sites of cleared virus become lesion sites associated with MS-like pathology when experimental autoimmune encephalomyelitis (EAE) is subsequently induced. EAE lesions contain high levels of inflammatory leukocytes that infiltrate because the sites of cleared virus are long-term sites of production of CCL5, a natural ligand of the chemokine receptor CCR5. Systemic administration of Orion Biotechnology's best-in-class CCR5 blocker OB-002 was sufficient to fully block both the development of these leukocyte-infiltrated lesions and the associated pathology.
"It is very exciting to have identified a possible pathway linking virus infection early in life to MS pathology, and intriguing that it should be dependent on the activation of a single chemokine receptor," said Prof. Merkler.
"We are thrilled to see that OB-002 shows such high efficacy in this preclinical context," said Professor Oliver Hartley, a co-author of the paper from the University of Geneva, and Vice-President for Drug Discovery at Orion Biotechnology. "These data provide a clear rationale to move forward with the development of OB-002 as novel agent for the treatment of MS."
Mark Groper, President & CEO of Orion Biotechnology, commented, "We are pleased to be working with the University of Geneva and look forward to further collaboration based on these encouraging preclinical findings."
1
